Showing 3491-3500 of 4178 results for "".
- Galderma Moves to Differentiate Their Two New HA Fillers From The Frayhttps://practicaldermatology.com/news/galderma-moves-to-differentiate-their-two-new-ha-fillers-from-the-fray/2458262/With a growing number of hyaluronic acid (HA) fillers available and even more in the pike, Galderma is highlighting how their two newest fillers --Restylane Refyne and Restylane Defyne --stand out from the crowd. In a word: flexibility. Th
- AAD Launches SkinSerious Campaignhttps://practicaldermatology.com/news/aad-launches-skinserious-campaign/2458268/The American Academy of Dermatology is launching a new campaign to raise awareness of the breadth of serious skin diseases as well as the critical role dermatologists play in an era of team-based health care. The SkinSerious campaign will launc
- Skin Diseases Remain Major Cause of Disabilityhttps://practicaldermatology.com/news/skin-diseases-remain-major-cause-of-disability/2458267/Skin diseases are the fourth leading cause of disability worldwide, according to the Global Burden of Disease 2013 Study which appears online in JAMA Dermatology. For the study, researchers estimate
- ACLARIS files NDA For Novel Seborrheic Keratosis Treatmenthttps://practicaldermatology.com/news/aclaris-files-nda-for-novel-seborrheic-keratosis-treatment/2458272/Aclaris Therapeutics, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for A-101 40% topical solution (A-101) as a treatment for seborrheic keratosis (SK). If approved, A-101 would be the first FDA-approved t
- Obagi Medical Products Collaborates with Suzan Obagi, MD and Nextcell Medical to Introduce New Linehttps://practicaldermatology.com/news/obagi-medical-products-collaborates-with-suzan-obagi-md-and-nextcell-medical-to-introduce-new-line/2458274/Valeant Pharmaceuticals International, Inc.’s wholly owned subsidiary Obagi Medical Products collaborated with Nextcell Medical Company to claim exclusive distribution of Suzan Obagi, MD’s line of skin care products throughout the United States. Established in 2013 with cosmetic
- Suzanne Olbricht, MD, Named New Chief of Dermatology at Beth Israel Deaconess Medical Centerhttps://practicaldermatology.com/news/suzanne-olbricht-md-named-new-chief-of-dermatology-at-beth-israel-deaconess-medical-center/2458278/Suzanne Olbricht, MD, is the new Chief of Dermatology at Beth Israel Deaconess Medical Center (BIDMC) in Boston. She will also serve as President of the American Academy of Dermatology in 2018. From 1983 to 1997, Dr. Olbricht worked as a staff derma
- Save The Dates: ASLMS to Host 37th Annual Conference In Early April 2017https://practicaldermatology.com/news/save-the-dates-aslms-to-host-37th-annual-conference-in-early-april-2017/2458279/American Society for Laser Medicine and Surgery (ASLMS) 2017 will take place April 5 – 9, 2017 in San Diego, Calif. New for 2017 is a special CME Session, Moving from the Lab to the Clinic, which will focus on the translation of technolog
- No Biopsy Required? Non-Invasive Skin Cancer Test May Offer Quick Diagnosishttps://practicaldermatology.com/news/no-biopsy-required-non-invasive-skin-cancer-test-may-offer-quick-diagnosis/2458284/A new non-invasive imaging technique may accurately detect skin cancer without surgical biopsy. Multiphoton microscopy of mitochondria accurately identified melanomas and basal cell carcinomas by detecting abnormal clusters of mitochondria in both types of skin cancer, according to resear
- Ray Canole is New Chief Commercial Officer at Revision Skincarehttps://practicaldermatology.com/news/ray-canole-is-new-chief-commercial-officer-at-revision-skincare/2458287/Revision Skincare has announced the appointment of Ray Canole to the position of Chief Commercial Officer. He has over 15 years of business development and commercial related experience in dermatology-focused organizations and joins Revision from Renaissance Pharma, where he helped
- Hologic to Acquire Cynosurehttps://practicaldermatology.com/news/hologic-to-acquire-cynosure/2458288/Hologic, Inc. and Cynosure, Inc. have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, which corresponds to an equity value of approximately $1.65 billi